National Academy of Sciences
National Academy of Engineering
Institute of Medicine
National Research Council
Office of News and Public Information
National Academy of Engineering
Back | Home
News from the National Academies

Read Full Report

Date:  May 12, 2010

Contacts:  Christine Stencel, Senior Media Relations Officer

Alison Burnette, Media Relations Assistant

Office of News and Public Information

202-334-2138; e-mail <news@nas.edu>

 

for immediate release

 

IOM Report Recommends Framework to Evaluate Science Behind Health Claims for Foods and Drugs; Calls for Equal Rigor in Assessing Food Claims and Drug Approvals

 

WASHINGTON -- The U.S. Food and Drug Administration (FDA) should apply the same rigor to evaluating the science behind claims of foods' and nutritional supplements' health benefits as it devotes to assessing medication and medical technology approvals, says a new report from the Institute of Medicine.  There are no scientific grounds for using different standards of evidence when evaluating the health benefits of food ingredients and drugs given that both can have significant impacts on people's well-being, said the committee that wrote the report.  It recommended a new framework the agency can use to consistently and transparently judge the appropriateness and validity of the scientific benchmarks used in studies that companies provide to support health and safety claims for their products. 

 

Because it can be time-consuming and difficult to test products against actual clinical outcomes -- such as whether they cure or reduce the risk of a disease -- companies often conduct studies measuring effects on biomarkers, which are used as biological yardsticks or substitutes for clinical outcomes.  For example, tumor size is used as a way to measure a cancer drug's effectiveness.  Blood level of harmful cholesterol is often used as a biomarker for the risk of heart disease, and drug and food companies make claims about the heart health benefits of their products based on their ability to lower cholesterol levels, even if the products have not been shown to actually decrease heart disease. 

 

FDA has been hampered in its ability to assess the proliferation of health claims being made by food and supplement manufacturers in part because it lacks a process broadly accepted across the regulatory, food, and medical communities to evaluate biomarkers as valid and appropriate measurements to substitute for clinical outcomes.  The committee's proposed three-part framework gives the agency a way to consistently and rigorously assess the selection and use of biomarkers across the food, device, and drug areas.    

 

In addition, the report calls on Congress to boost the agency's authority to require further studies of drugs and devices after they are approved if their approval is based on studies using biomarkers as surrogate clinical outcomes.  And Congress should give FDA the authority to conduct studies of how well consumers understand food and supplement health claims and require manufacturers to make changes if needed to promote greater clarity.

 

"Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medications, and this committee thinks that should in fact be the case," said committee chair John Ball, executive vice president, American Society for Clinical Pathology, Chicago.  "Without changes in the way biomarkers are used and assessed, however, health care providers, regulators, and consumers will not be able to reliably collect or judge information to support claims."

 

The proposed framework entails validating that a biomarker can be accurately measured, ensuring that it is associated with the clinical outcome of concern, and confirming that it is appropriate for the proposed use.  Committee members demonstrated the kinds of information and lessons the framework can provide by doing several case studies, looking at tumor size as a biomarker for cancer, blood level of beta-carotene as a surrogate for cancer and cardiovascular disease risk, and cholesterol level as an indicator of heart disease, among others.

 

The report calls for Congress to enhance FDA's abilities to study how health-related information can be communicated more effectively to consumers to help them better understand the science behind claims they see on packaging.  The typical consumer is not aware that claims for food ingredients and supplements are often made based on studies using biomarkers instead of actual health outcomes, and that this introduces a measure of uncertainty.

 

FDA also needs the resources and authority to act on claims when they are found to cause confusion or to exceed regulatory limits.  A report issued by Rep. Henry Waxman's office noted that FDA enforcement of food and supplement health claims declined by more than 50 percent from 2000 to 2005.  However, recent actions by the FDA indicate it is engaging in heightened enforcement of food labeling, including health claims.

 

The report was sponsored by the U.S. Food and Drug Administration.  Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public.  The National Academy of Sciences, National Academy of Engineering, Institute of Medicine, and National Research Council make up the National Academies.  A committee roster follows.

 

Copies of Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease are available from the National Academies Press; tel. 202-334-3313 or 1-800-624-6242 or on the Internet at http://www.nap.edu.  Reporters may obtain a copy from the Office of News and Public Information (contacts listed above). 

#       #       #

 

[ This news release and report are available at http://national-academies.org ]

 

INSTITUTE OF MEDICINE

Food and Nutrition Board

Board on Health Care Services

Board on Health Sciences Policy

 

Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease

 

John R. Ball M.D., J.D. (chair)

Executive Vice President

American Society for Clinical Pathology

Chicago

 

Michelle A. Albert, M.D., M.P.H.

Assistant Professor of Medicine, and

Associate Physician, and

Director of Behavioral and Neurocardiovascular Cardiology

Bringham and Women's Hospital, Harvard University

Boston

 

Fred Apple, Ph.D.

Professor

Department of Laboratory Medicine and Pathology

University of Minnesota Medical School;

and

Medical Director, Clinical Laboratories

Hennepin County Medical Center

Minneapolis

 

Robert M. Califf, M.D.

Vice Chancellor

Clinical and Translational Research, and

Director

Duke Translational Medical Institute, and

Professor of Medicine

Division of Cardiology

School of Medicine

Duke University

Durham, N.C.

 

Victor G. De Gruttola, Sc.D.

Chair and Professor

Department of Biostatistics

School of Public Health

Harvard University

Boston

 

David L. DeMets, Ph.D.

Professor of Statistics and Biostatistics

Department of Biostatistics and Medical Informatics

University of Wisconsin

Madison

 

Rob Gerszten, M.D.

Associate Professor of Medicine

Cardiovascular Research Center

Massachusetts General Hospital

Boston

 

William R. Harlan Jr., M.D., FACP, FACPM, FAAFP, FAHA

Consultant

Chevy Chase, Md.

 

Allan S. Jaffe, M.D.

Professor of Medicine

Cardiovascular Diseases Division

Department on Laboratory Medicine and Pathology

College of Medicine

Mayo Clinic

Rochester, Minn.

 

Ronald M. Krauss, M.D.

Director

Atherosclerosis Research

Children’s Hospital Oakland Research Institute, and

Senior Scientist

Life Sciences Division

Lawrence Berkeley National Laboratory

Oakland, Calif.

 

Harlan M. Krumholz, M.D., S.M.

Harold H. Hines Professor of Medicine and Epidemiology and Public Health

School of Medicine

Yale University

New Haven, Conn.

 

Maria Lopes-Virella, M.D. Ph.D. 

Professor

Immunology and Microbiology Department

Division of Endocrinology, Diabetes, and Medical Genetics

Medical University of South Carolina

Charleston

 

Roberta B. Ness, M.D., M.P.H.

Dean and M. David Low Chair in Public Health

School of Public Health

University of Texas

Houston

Jenny van Eyk, Ph.D.

Associate Professor of Physiology and Biochemistry

Johns Hopkins University

Baltimore

 

John A. Wagner, M.D., Ph.D.

Vice President

Clinical Pharmacology

Merck and Co.

Rahway, N.J.



STUDY STAFF

 

Christine Micheel, Ph.D.

Study Director

 

Elizabeth Yetley

Consultant

Office of Dietary Supplements

National Institutes of Health